{"id":6800,"date":"2023-05-03T15:45:00","date_gmt":"2023-05-03T15:45:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/"},"modified":"2023-05-03T15:45:00","modified_gmt":"2023-05-03T15:45:00","slug":"nanexa-publicerar-arsredovisning-for-2022","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/","title":{"rendered":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2022"},"content":{"rendered":"
\n

Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2022 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida <\/strong>www.nanexa.com\/finansiella-rapporter<\/a><\/strong>.<\/strong><\/p>\n

\u201d2022 var ett \u00e5r d\u00e5 vi tog stora steg mot kommersialisering av v\u00e5rt PharmaShell\u00ae system. Vi sl\u00f6t fyra nya utv\u00e4rderingsavtal, inte minst ett med Novo Nordisk som \u00e4ven inkluderade en
4 MUSD betalning f\u00f6r en specifik exklusivitet under utv\u00e4rderingsperioden. Vi har \u00e4ven gjort viktiga framsteg i v\u00e5ra egna utvecklingsprojekt d\u00e4r vi nu tagit in NEX-20 (enm\u00e5nadsdep\u00e5
av lenalidomid) i klinisk fas \u2013 och vi har initierat ett nytt projekt med mycket stor potential inom typ-2 diabetes, NEX-22 (enm\u00e5nadsdep\u00e5 av liraglutid). I NEX-18 projektet har vi identifierat m\u00f6jliga f\u00f6rb\u00e4ttringar av formuleringen f\u00f6r att eliminera hudp\u00e5verkan och forts\u00e4tta produktutvecklingen. I diskussion med v\u00e5rt vetenskapliga r\u00e5d identifierades \u00e4ven en m\u00f6jlighet att p\u00e5visa en b\u00e4ttre effekt \u00e4n originalprodukten Vidaza, en m\u00f6jlighet baserad p\u00e5 v\u00e5r l\u00e5nga fris\u00e4ttning som vi bed\u00f6mer \u00e4r v\u00e4rd att utv\u00e4rdera.\u201d, s\u00e4ger David Westberg, vd p\u00e5 Nanexa.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa AR 2022 SVE<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2022 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter<\/a>.<\/p>\n

\u201d2022 var ett \u00e5r d\u00e5 vi tog stora steg mot kommersialisering av v\u00e5rt PharmaShell\u00ae system.<\/p>\n

L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-6800","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa publicerar \u00e5rsredovisning f\u00f6r 2022 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2022 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2022 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter. \u201d2022 var ett \u00e5r d\u00e5 vi tog stora steg mot kommersialisering av v\u00e5rt PharmaShell\u00ae system.L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2022\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2022\\\/\",\"name\":\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2022 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2023-05-03T15:45:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2022\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-arsredovisning-for-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2022 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2022 - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att \u00e5rsredovisningen f\u00f6r 2022 har offentliggjorts och finns tillg\u00e4nglig p\u00e5 bolagets hemsida www.nanexa.com\/finansiella-rapporter. \u201d2022 var ett \u00e5r d\u00e5 vi tog stora steg mot kommersialisering av v\u00e5rt PharmaShell\u00ae system.L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/","name":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2022 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2023-05-03T15:45:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-arsredovisning-for-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar \u00e5rsredovisning f\u00f6r 2022"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}